That is equal to .1385 pre-reverse split!
It's equivalent to .142
That is equivalent to .147 per share pre-reverse split adjusted.
Sentiment: Strong Sell
Revenues mean nothing. Income is the key, which is negative for NSPH.
Now factor in three dilutive financings since last fall, the latest two with the last 60 days resulting in 60% dilution just for those two.
Now factor in the $20M in debt they took on last month and the additional $10M in debt they can now take on due to this weeks latest dilution.
Finally, factor in their problems with the FDA....the warning letter they received earlier this year.
They are lucky that the market cap is as high as $18.2M!
Like I pointed out in your last absurd post, you are calculating imaginary numbers since the only reported revenues this year are from Q1!
Hilarious stuff from the pumpers!
Since no revenues have been reported for anything other than Q1, you are calculating imaginary numbers!
You irrational pumpers are posting some outrageously funny stuff over the last two days!
Oh yeah, what is your excuse for vastly overstating the market cap yesterday? I can't wait you see your absurd answer for that!
Oh yeah....NSPH's market cap is only $18.2M, not the $25M you claimed.
It appears the scammers are trying hard today to lure in new bag holders.
Annual revenues last year were only $14M and won't be much better this year.
You need to go back to school and take remedial math.
He is so egocentric he thinks everyone lives in his time zone and doesn't understand that other people from elsewhere in North America and other parts of the world post here at all hours of the day and night
With regard to their constant litigation, they are nothing but patent trolls.
Other than that, they keep skirting the FDA regulations as they have with their new HPV/cytology test performed on a flow cytometer. The FDA REQUIRES all HPV tests and cervical cytology tests be submitted to the FDA and not only did ENZ not do that, they have also made unfounded clinical util;ity claims for the test.
I noticed that too. Bipolar doesn't even begin to describe bheard.
Sour grapes by bheard! He knows the significance of the loss of Christine Ginocchio to bioMerieux because they have better tests.
Remember all the sepsis testing studies NSPH has on its website done by Christine Ginocchio, Ph.D.?
The ones dealing with sepsis testing? Just how impressed was she with NSPH's tests?
Here is a hint, she left Northshore Health-LIJ Hospital System and is now VP, Global Microbiology Affairs at bioMérieux. I guess she knows which company's tests are the best.